Cellular and molecular mechanisms of action of bisphosphonates

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer

• Publication date

  2000-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-LPMID 10898340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-activity relationships of various bisphosphonates

  2006cited by this paper
• Influence of a diphosphonate on the cellular aspect of young bone tissue

  2006cited by this paper
• The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells

  2006cited by this paper
• The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatitein vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats

  2005cited by this paper
• Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate

  2004cited by this paper
• Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

  1999cited by this paper
• Reversibility of alendronate-induced contraction in human osteoclast-like cells formed from bone marrow cells in culture

  1999cited by this paper
• Etidronate (EHDP) Inhibits Osteoclastic-Bone Resorption, Promotes Apoptosis and Disrupts Actin Rings in Isolate-Mature Osteoclasts

  1999cited by this paper
• Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.

  1999cited by this paper
• Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.

  1999influential reference
• The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen‐Containing Bisphosphonates

  1999cited by this paper
• Relationship between bisphosphonate concentration and osteoclast activity and viability

  1999cited by this paper
• Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment.

  1999cited by this paper
• Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

  1999cited by this paper
• Integrin-mediated Signals Regulated by Members of the Rho Family of GTPases

  1998cited by this paper
• Heterocycle‐Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure‐Activity Relationships in J774 Macrophages

  1998cited by this paper
• Human Osteoclast Formation and Activity In Vitro: Effects of Alendronate

  1998cited by this paper
• Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs.

  1998cited by this paper
• The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

  1998cited by this paper
• Alendronate Reduces Adhesion of Human Osteoclast-like Cells to Bone and Bone Protein-Coated Surfaces

  1998cited by this paper
• Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.

  1998cited by this paper
• Comparison of Cytotoxic Effects of Bisphosphonates In Vitro and In Vivo

  1998cited by this paper
• Differential Effects of Aminosubstituted Analogs of Hydroxy Bisphosphonates on the Growth of Dictyostelium discoideum

  1998cited by this paper
• Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras

  1998cited by this paper
• Inhibition of Growth of Dictyostelium discoideum Amoebae by Bisphosphonate Drugs Is Dependent on Cellular Uptake

  1997cited by this paper
• Alendronate inhibition of protein-tyrosine-phosphatase-meg1.

  1997cited by this paper
• Clodronate and Liposome‐Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 5′‐(β,γ‐Dichloromethylene) Triphosphate, by Mammalian Cells In Vitro

  1997cited by this paper
• Osteoclast activation: Potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism

  1997cited by this paper
• Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.

  1997cited by this paper
• Phosphite Addition to Carbonyl Group and Phosphoryl Migration Under Phase Transfer Catalytic Circumstances

  1997cited by this paper
• The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.

  1997cited by this paper
• How Does Alendronate Inhibit Protein-tyrosine Phosphatases?*

  1997cited by this paper
• Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.

  1997cited by this paper
• Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.

  1997cited by this paper
• Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

  1997cited by this paper
• Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts.

  1997cited by this paper
• Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group

  1996cited by this paper
• Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes.

  1996cited by this paper
• The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+‐ATPase

  1996cited by this paper
• Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones.

  1996cited by this paper
• Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates.

  1996cited by this paper
• Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures.

  1996cited by this paper
• Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

  1996cited by this paper
• Modulation of adhesion-dependent cAMP signaling by echistatin and alendronate.

  1996cited by this paper
• Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.

  1996cited by this paper
• 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.

  1996cited by this paper
• Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate.

  1996cited by this paper
• Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.

  1996cited by this paper
• Bisphosphonates induce apoptosis in mouse macrophage‐like cells in vitro by a nitric oxide‐independent mechanism

  1996cited by this paper
• Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.

  1996cited by this paper
• Human protein tyrosine phosphatase‐σ: Alternative splicing and inhibition by bisphosphonates

  1996cited by this paper
• Elucidation of a Pharmacophore for the Bisphosphonate Mechanism of Bone Antiresorptive Activity

  1996cited by this paper
• Bisphosphonates: a review of their pharmacokinetic properties.

  1996cited by this paper
• Protein prenylation: molecular mechanisms and functional consequences.

  1996cited by this paper
• A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.

  1995cited by this paper
• The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts.

  1995cited by this paper
• Tiludronate: bone pharmacology and safety.

  1995cited by this paper
• Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.

  1995cited by this paper
• Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.

  1995cited by this paper
• Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.

  1995cited by this paper
• Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

  1995cited by this paper
• Section Review: Oncologic, Endocrine & Metabolic: The vacuolar H+-ATPase: A potential target for drug development in bone diseases

  1995cited by this paper
• The effects of bisphosphonates on the resorption cycle of isolated osteoclasts

  1994cited by this paper
• Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.

  1994cited by this paper
• Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound

  1994cited by this paper
• Effects of two novel bisphosphonates on bone cells in vitro.

  1994cited by this paper
• Structural requirements for bisphosphonate actions in vitro

  1994cited by this paper
• Pamidronate stimulates recruitment and decreases longevity of osteoclast nuclei in mice.

  1994cited by this paper
• Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold dictyostelium discoideum

  1994cited by this paper
• Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo

  1993cited by this paper
• Bisphosphonates: Molecular Modelling, Structure-Activity Relationships and the Rational Design of New Analogs

  1993cited by this paper
• Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

  1993cited by this paper
• Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.

  1992cited by this paper
• Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.

  1992cited by this paper
• Disodium 1‐hydroxy‐3‐(1‐pyrrolidinyl)‐propylidene‐1,1‐bisphosphonate (EB‐1053) is a potent inhibitor of bone resorption in vitro and in vivo

  1992cited by this paper
• The small GTP-binding protein rac regulates growth factor-induced membrane ruffling.

  1992cited by this paper
• The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.

  1992cited by this paper
• Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study.

  1992cited by this paper
• Sensitivity to vanadate and isoforms of subunits A and B distinguish the osteoclast proton pump from other vacuolar H+ ATPases.

  1992cited by this paper
• Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum.

  1992cited by this paper
• Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

  1991influential reference
• Modulation of PTH‐stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants

  1991cited by this paper
• Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone

  1991cited by this paper
• BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

  1991cited by this paper
• DESIGNING DRUGS FOR STRONGER BONES

  1991cited by this paper
• Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy

  1990cited by this paper
• Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage

  1990cited by this paper
• Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.

  1990cited by this paper
• Effects of (3‐amino‐1‐hydroxypropylidene)‐1,1‐bisphosphonate on mouse osteoclasts

  1990cited by this paper
• The Design and Synthesis of Bone-Active Phosphinic Acid Analogues: 1. The Pyridylaminomethane Phosphonoalkylphosphinates

  1990cited by this paper
• Antiresorptive dose-response relationships across three generations of bisphosphonates.

  1989cited by this paper
• Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

  1989cited by this paper
• Osteoclastic bone resorption by a polarized vacuolar proton pump.

  1989cited by this paper
• Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

  1989cited by this paper
• Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone.

  1989cited by this paper
• Methylenediphosphonate, a metabolic poison in Dictyostelium discoideum. Phosphorus-31 NMR evidence for accumulation of adenosine 5'-(.beta.,.gamma.-methylenetriphosphate) and diadenosine 5',5'''-P1,P4-(P2,P3-methylenetetraphosphate)

  1988cited by this paper
• Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone.

  1988cited by this paper
• Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate

  1988cited by this paper
• Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro.

  1987cited by this paper
• Effect of bisphosphonates on proliferation and viability of mouse bone marrow‐derived macrophages

  1987cited by this paper

• Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

  2026cites this paper
• THE CHIMERIC ALT-VASTUS LATERALIS FREE FLAP IN RECONSTRUCTION OF ADVANCED BRONJ OF THE MAXILLA

  2026cites this paper
• Osteoclast-derived exosomes promote medication-related osteonecrosis of the jaw by delivering glycoRNA to disrupt the blood–lymphatic vascular network

  2026cites this paper
• Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis

  2026cites this paper
• Dental Implant Survival and Risk of Medication-Related Osteonecrosis in the Jaws in Patients Undergoing Antiresorptive Therapy: A Systematic Review

  2025cites this paper
• Consequence of Bisphosphonate Use on Dental Implant Removal in Osteoporotic Patient: A Nationwide Cohort Study.

  2025cites this paper
• Use of Bisphosphonates and The Effect of Osteonecrosis of The Jaw – Review

  2025cites this paper
• Cytotoxic Activity of Bisphosphonic Derivatives Obtained by the Michaelis–Arbuzov or the Pudovik Reaction

  2025cites this paper
• Attributable Risk and Consequences of Bone Mineral Density Deficits in Childhood Cancer Survivors

  2025cites this paper
• Risk assessment and drug interruption guidelines for dentoalveolar surgery in patients with osteoporosis receiving anti-resorptive therapy

  2025cites this paper
• Fabrication and evaluation of the zoledronic acid loaded cationic starch-hydroxyapatite-ZrO2 nanocomposites for bone disease treatment

  2025cites this paper
• Broad-spectrum antiviral activity of ebselen

  2025cites this paper
• Osteoclast-Derived Exosomes Promote MRONJ via the VEGFR2-Caspase9 and Notch1-Hes1/Hey Signaling Pathways.

  2025cites this paper
• Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies, and Management

  2025cites this paper
• Fracture line sequestration: An important complication of open mandibular fractures in three horses

  2025cites this paper
• 99mTc-radiolabeling study of 2-amino-3-(4-hydroxyphenyl)-1-hydroxypropyl-1,1-bisphosphonic acid as a potential bone imaging agent

  2025cites this paper
• Dynamic alterations in M2 macrophage subtypes enhance flap expansion efficiency and tissue regeneration

  2024cites this paper
• Engineering Small Molecule and Protein Drugs for Targeting Bone Tumors.

  2024cites this paper
• Effect of Local Zoledronic Acid Application in Alveolar Bone Healing: An Experimental Study

  2024cites this paper
• No increased risk of osteonecrosis of the jaw in osteoporotic patients with dental implants: a nationwide cohort study

  2024cites this paper
• Clinical Performance of Implant-Supported Prostheses in the Rehabilitation of Patients Previously Treated for Medication-Related Osteonecrosis of the Jaws (MRONJ): A Systematic Review

  2024cites this paper
• The effectiveness of autologous platelet concentrates in prevention and treatment of medication-related osteonecrosis of the jaws: A systematic review.

  2024cites this paper
• A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer

  2024influential citation
• Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity

  2024cites this paper
• Medications and Orthodontic Tooth Movement: What Accelerates and Diminishes Tooth Movement?

  2024cites this paper
• Beta-adrenergic receptor antagonist propranolol prevents bisphosphonate-related osteonecrosis of the jaw by promoting osteogenesis

  2024cites this paper
• AI and Conventional Techniques used for Drugs and Orthodontic Tooth Movement

  2024cites this paper
• Evaluation of trabecular bone changes according to the type of prosthesis in patients using bisphosphonates: a retrospective study.

  2023cites this paper
• Nanotechnologies and controlled release formulations for the administration of bisphosphonates and their potential in radiation protection

  2023cites this paper
• Alendronate augments lipid A‑induced IL‑1β release by ASC‑deficient RAW264 cells via AP‑1 activation.

  2023cites this paper
• Management of metastatic bone disease of melanoma.

  2023cites this paper
• Novel insights into the pharmacological modulation of human periodontal ligament stem cells by the amino-bisphosphonate Alendronate.

  2023cites this paper
• Oral fibroblasts rescue osteogenic differentiation of mesenchymal stem cells after exposure to Zoledronic acid in a paracrine effect

  2023cites this paper
• The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells

  2023cites this paper
• Zinc Zeolite as a Carrier for Tumor Targeted and pH-responsive Drug Delivery

  2023cites this paper
• Use of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw

  2023cites this paper
• Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates.

  2023cites this paper
• Zoledronic acid improves bone quality and muscle function in a high bone turnover state

  2023cites this paper
• Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting breast cancer secondary metastasis

  2023cites this paper
• Effects of zoledronic acid on osteosarcoma progression and metastasis: systematic review and meta‐analysis

  2022cites this paper
• Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases

  2022cites this paper
• Host-Guest Interaction of Anti-Carcinogenic Drug Zoledronic Acid with β-Cyclodextrin in Solid and Solution Forms

  2022cites this paper
• Effect of local administration of bisphosphonate on orthodontic anchorage – A systematic review of animal studies

  2022cites this paper
• Rescue of the increased susceptibility to Mild Chronic Oxidative Stress of iNeurons carrying the MAPT Chromosome 17q21.3 H1/H1 risk allele by FDA-approved compounds

  2022cites this paper
• Pathophysiology and therapeutic advances in myeloma bone disease

  2022cites this paper
• Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation

  2022cites this paper
• Effects of Type 2 Diabetes Mellitus on Osteoclast Differentiation, Activity, and Cortical Bone Formation in POSTmenopausal MRONJ Patients

  2022cites this paper
• Targeting a therapeutically relevant concentration of alendronate for in vitro studies on osteoblasts

  2022cites this paper
• Awareness of patients receiving bisphosphonates: a cross-sectional study.

  2022cites this paper
• Phosphorylated and Phosphonated Low‐Complexity Protein Segments for Biomimetic Mineralization and Repair of Tooth Enamel

  2022cites this paper
• A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw

  2022cites this paper
• Bisphosphonate affects the behavioral responses to HCl by disrupting farnesyl diphosphate synthase in mouse taste bud and tongue epithelial cells

  2022cites this paper
• The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies

  2021cites this paper
• Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate

  2021cites this paper
• POTENTIAL APPLICATIONS OF BISPHOSPHONATES IN PERIODONTAL DISEASES

  2021cites this paper
• Myeloma Bone Disease: A Comprehensive Review

  2021cites this paper
• Drug Delivery to the Bone Microenvironment Mediated by Exosomes: An Axiom or Enigma

  2021cites this paper
• Mechanism, prevention, and treatment for medication-related osteonecrosis of the jaws.

  2021cites this paper
• Adverse events associated with bone-directed therapies in patients with cancer.

  2021cites this paper
• Role of the calcium-sensing receptor (CaSR) in cancer metastasis to bone: Identifying a potential therapeutic target.

  2021cites this paper
• Geranylgeraniol prevents zoledronic acid-mediated reduction of viable mesenchymal stem cells via induction of Rho-dependent YAP activation

  2021cites this paper
• Comparison of the Effect of Oral Versus Intravenous Bisphosphonate Administration on Osteoclastogenesis in Advanced-Stage Medication-Related Osteonecrosis of the Jaw Patients

  2021cites this paper
• Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive K+ Channels: Role in the Adverse Drug Reactions

  2021cites this paper
• Dosimetry of bone seeking beta emitters for bone pain palliation metastases.

  2021cites this paper
• A Mechanistic Study on the Formation of Dronic Acids

  2021cites this paper
• Bisphosphonate nephropathy: A case series and review of the literature

  2021cites this paper
• Synergistic use of biomaterials and licensed therapeutics to manipulate bone remodelling and promote non-union fracture repair.

  2020cites this paper
• Zoledronate promotes inflammatory cytokine expression in human CD14‐positive monocytes among peripheral mononuclear cells in the presence of γδ T cells

  2020cites this paper
• Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review

  2020cites this paper
• Structure-Dependent Effects of Bisphosphonates on Inflammatory Responses in Cultured Neonatal Mouse Calvaria

  2020cites this paper
• Could medications and biologic factors affect post orthodontic tooth movement changes? a systematic review of animal studies.

  2020cites this paper
• Actualización de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisión de literatura

  2020cites this paper
• Biofunctionalization of Textile Materials. 2. Antimicrobial Modification of Poly(lactide) (PLA) Nonwoven Fabricsby Fosfomycin

  2020cites this paper
• Rate of implant failure in patients on antiresorptive drugs: a clinical investigation

  2020cites this paper
• Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study

  2020cites this paper
• What Do We Know About Clodronate Now? A Medical and Veterinary Perspective.

  2020cites this paper
• Successful treatment of calciphylaxis with bisphosphonates in kidney transplant recipients suffering from secondary hyperparathyroidism: A report of two cases

  2020cites this paper
• Are There Contraindications for Placing Dental Implants?

  2019cites this paper
• Effects of systematic bisphosphonate use in patients under orthodontic treatment: a systematic review.

  2019cites this paper
• Bisphosphonates and cancer: A relationship beyond the antiresorptive effects.

  2019cites this paper
• Characteristics of polymeric materials used in medicine

  2019cites this paper
• Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer

  2019cites this paper
• Chronic Recurrent Multifocal Osteomyelitis of the Hand: A Rare Pediatric Condition

  2019cites this paper
• Histologic and Radiographic Characteristics of Bone Filler Under Bisphosphonates.

  2019cites this paper
• Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates

  2019cites this paper
• Host Modulation Therapy- An Adjunctive Treatment Modality

  2019cites this paper
• Characterization of urinary biomarkers and their relevant mechanisms of zoledronate-induced nephrotoxicity using rats and HK-2 cells

  2019cites this paper
• Prevention of ovariectomy-induced osteoporosis in rats

  2019cites this paper
• WY 1048, a 17-methyl 19-nor D-ring analog of vitamin D3, in combination with risedronate restores bone mass in a mouse model of postmenopausal osteoporosis.

  2019cites this paper
• The Bone Extracellular Matrix as an Ideal Milieu for Cancer Cell Metastases

  2019cites this paper
• Antiproliferative and antimigratory activities of bisphosphonates in human breast cancer cell line MCF-7

  2019cites this paper
• Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study

  2019cites this paper
• Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells.

  2019cites this paper
• Hypercalcemia of Malignancy

  2019cites this paper
• Bisphosphonate-based ionic liquids as potential pharmacological tools for breast cancer-induced bone osteolytic metastasis

  2018cites this paper
• Transcriptomic profiling of tantalum metal implant osseointegration in osteopenic patients

  2018cites this paper
• Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology

  2018cites this paper
• Management of multiple myeloma bone disease: impact of treatment on renal function

  2018cites this paper
• Bone repair potential of human amniotic fluid stem cells

  2018cites this paper
• Determination of Zoledronic Acid and Its Related Substances by High Performance Liquid Chromatography with Evaporative Light Scattering Detection.

  2018cites this paper